INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Incyte Corporation

1801 Augustine Cut-Off
Wilmington, DE 19803
United States
302-498-6700
http://www.incyte.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees1,208

Key Executives

NameTitlePayExercisedYear Born
Mr. Hervé HoppenotChairman, Pres & CEO2.28MN/A1960
Mr. David W. Gryska MBAExec. VP & CFO903.11kN/A1955
Dr. Reid M. HuberExec. VP & Chief Scientific Officer798.32k1.22M1972
Dr. Wenqing YaoExec. VP & Head of Discovery Chemistry719.59k367.43k1963
Dr. Steven H. SteinExec. VP & Chief Medical Officer724.61kN/A1967
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naïve acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.

Corporate Governance

Incyte Corporation’s ISS Governance QualityScore as of April 1, 2018 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.